In addition, T3 treatment prior to brain ischemia (25 μg/kg intravenous) has prevented edema through suppression of aquaporin-4 (AQP4) water channel expression and thereby reducing infarct volume and improving neurological outcome after transient MCAO (109), effects that were enhanced when T3 was administrated in nanoparticles at equivalent doses (108). The gene discussed is AQP4; the disease is brain ischemia.